Genomics
PrivateLast Round
VC Round
Jan 8, 2024
Est. Valuation
$40.66M
Total Funding Raised
$58.86M
Company Overview
Genomics operates in Healthcare & Life Sciences and is based in Oxford, England. Its latest recorded funding round was a VC Round in January 2024.
Genomics is a biotechnology company that specializes in genetic inference technology to identify new drug targets for serious diseases, utilizing an analytical platform to enhance DNA sequencing impact and support pharmaceutical firms in de-risking drug development while improving healthcare outcomes.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Precision Medicine, Healthcare Analytics, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genomics Comparables
Compare Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Variant Bio | 79% | |
| Helix | 79% | |
| Quantgene | 77% |
For institutional investors. Book with your work email.
Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jan 8, 2024 | ||||
| VC Round | Mar 1, 2021 | ||||
| Series B | Dec 10, 2018 | ||||
| Series A | Nov 26, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Infinity Investment Partners | VC Round |
| IP Group | Series A, Series B |
| Oxford Science Enterprises | Series B, VC Round |
| F-Prime Capital | Series B, VC Round |
| Tanarra | Series B |
| University of Oxford | Series A |
| Woodford Investment Management | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 30, 2026
Partnered with Greywolf to develop ERAP autoimmune disease treatments.
- Apr 30, 2026
Developing first-in-class ERAP autoimmune disease treatments with Greywolf.
For institutional investors. Book with your work email.
Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Genomics's valuation, stock price, and market status.
Is Genomics a public or private company?
Genomics is a private company.
What is the current stock price of Genomics?
Genomics is a private company, so its shares have no public market price. Caplight tracks Genomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Genomics worth (valuation)?
Genomics's valuation is estimated at $40.7M based on funding round data.
Can I buy Genomics stock?
Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Genomics's last funding round?
Genomics's most recent funding round was VC Round on January 8, 2024.
Who are the main investors in Genomics?
Key investors in Genomics include F-Prime Capital, Foresite Capital.
Will Genomics IPO soon?
No public IPO plans have been announced for Genomics.
How can I track Genomics secondary market activity?
Caplight tracks bids, offers, and trades in Genomics's shares on secondary markets.